Lise Loberg, PhD, DABT, PMP

Dr. Loberg has 20 years’ experience in drug development as a toxicologist and project manager in the biopharmaceutical industry.  Dr. Loberg’s current role is Scientific Director in an Emerging Therapeutic Platforms group; in this role she manages teams in preclinical safety, drug metabolism and pharmacokinetics, process chemistry, and formulations development to advance novel technical platforms from discovery to development in oncology, immunology, and neuroscience.  Prior to this role, she led preclinical safety development of antibody-drug conjugates (ADC) for treatment of various tumor types. During her career at AbbVie, Dr. Loberg has worked in Preclinical Safety at three R&D sites (Ludwigshafen, Germany; Redwood City, California; and Lake County, Illinois), where she supported preclinical safety evaluation of compounds in development, from lead selection to late-stage clinical trials and marketed drugs. She has experience with large molecule biotechnologies and small molecule drugs ranging across several therapeutic areas including oncology, immune-oncology, neuroscience and renal disease. She also spent three years in Drug Development Project Management, where she supported Neuroscience Development as project manager for programs in preclinical, Phase I and Phase II stages of development. Dr. Loberg earned her PhD in Toxicology from the Department of Environmental Health at the University of Cincinnati, College of Medicine (1996) and her BS in Psychology/Neuroscience at John Carroll University. Prior to joining AbbVie, Dr. Loberg supervised a Molecular Toxicology laboratory at IIT Research Institute (1996-1999). Dr. Loberg is a Diplomate of the American Board of Toxicology and has earned the Project Management Professional (PMP) certification. She served as Treasurer (2011-2013) and Councilor (2010-2011) for the Midwest Regional Chapter of SOT and has been on the planning committee for Applied Pharmaceutical Toxicology annual symposia from 2012-2020.